Long Term Patient Outcomes and Product Durability of the Mosaic Mitral Valve Bioprosthesis in Patients Under 65
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
The safety and efficacy of the Mosaic bioprosthetic heart valves for cardiac valve replacement in the aortic position has been well documented throughout the literature. However, few studies assessing structural valve deficiency, patient outcomes and overall product performance in patients under the age of 65 exists for the Mosaic mitral valve bioprosthetic. This study aims to assess valve efficacy, stability, and post operative outcomes in patients who have received the Mosaic mitral valve prothesis at ProMedica Toledo Hospital and were under the age of 65.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:
• Received the Mosaic Mitral Valve Bioprosthetic at ProMedica Toledo Hospital
• Under the age of 65
Locations
United States
Ohio
ProMedica Toledo Hospital
RECRUITING
Toledo
Contact Information
Primary
Dawn Muskiewicz, MS
dawn.muskiewicz@promedica.org
419-291-7517
Backup
Leah Stevenson, MS
leah.stevenson@promedica.org
419-291-3419
Time Frame
Start Date: 2025-01-01
Estimated Completion Date: 2027-07-01
Participants
Target number of participants: 300
Treatments
Mitral Valve Replacement
Patients who have undergone mitral valve replacement at ProMedica Hospital using the mosaic bioprosthesis and were under the age of 65.
Related Therapeutic Areas
Sponsors
Leads: Michael Moront